Alkem Laboratories Announces Unaudited Financial Results for Quarter Ended Sep 30, 2025
Alkem Laboratories announced its unaudited financial results for the quarter ended September 30, 2025, with a total income of ₹40,009.9 lakh and a net profit of ₹7,650.6 lakh.
The financial results provide insights into the company's performance, which is relevant to investors and can influence stock prices.
The announcement is a routine disclosure of financial results, and the numbers presented are factual without any indication of positive or negative outlook.
* Alkem Laboratories Limited has released the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2025. * Total Income from Operations for the quarter stood at ₹40,009.9 lakh, and ₹73,721.3 lakh for the six months ended September 30, 2025. * Net Profit for the period after tax (after exceptional items) attributable to the owners of the Company was ₹7,650.6 lakh for the quarter and ₹14,293.2 lakh for the six months ended September 30, 2025. * Basic and Diluted Earnings Per Share (EPS) stood at ₹63.99 for the quarter and ₹119.55 for the six months ended September 30, 2025. * For standalone financial results: * Total Income from continuing Operations was ₹25,420.3 lakh for the quarter and ₹49,142.0 lakh for the six months ended September 30, 2025. * Profit After Tax from continuing operations was ₹7,236.6 lakh for the quarter and ₹13,459.2 lakh for the six months ended September 30, 2025. * The results were reviewed by the Audit Committee on November 12, 2025, and approved by the Board of Directors on November 13, 2025.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.